GSK launches single inhaler-triple therapy Trelegy Ellipta to treat COPD in India

Dr. Deepak Talwar, Director & Chair - Pulmonary, Sleep, Allergy & Critical Care Medicine at Metro Group of Hospitals, said, "COPD is associated with major healthcare and socioeconomic burden on patients and their caregivers. In appropriate patients, studies show that a combination of three different types of medicines for COPD can effectively improve patients' symptoms and reduce the risk of symptom worsening. Considering 75% COPD patients have four or more co-existing medical conditions, the burden of managing and taking many medications may overwhelm patients, resulting in suboptimal treatment. Single-inhaler triple therapy has the potential role to simplify treatment, improve treatment adherence and patient outcomes."

In usual clinical care, treatment with single-inhaler Trelegy Ellipta results in significantly more patients with health status improvements and greater lung benefit, versus multi-inhaler triple therapy, with similar safety profiles. Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers.

Read also: Glenmark gets CDSCO panel nod for Phase 4 study of anti-diabetic FDC drug